Citigroup’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Citigroup’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-348	Closed	-$2K	–	7835
2019 Q4	$2K	Hold	348	–	–	﹤0.01%	7569
2019 Q3	$2K	Sell	348 -120	-26%	-$827	﹤0.01%	7569
2019 Q2	$3K	Sell	468 -82	-15%	-$624	﹤0.01%	7586
2019 Q1	$6K	Sell	550 -2,075	-79%	-$20.7K	﹤0.01%	7397
2018 Q4	$21K	Buy	2,625 +1,000	+62%	+$14.4K	﹤0.01%	6863
2018 Q3	$31K	Sell	1,625 -3,938	-71%	-$71.7K	﹤0.01%	6876
2018 Q2	$101K	Buy	5,563 +5,063	+1,013%	+$74.7K	﹤0.01%	5717
2018 Q1	$5K	Buy	500 +175	+54%	+$2.81K	﹤0.01%	7225
2017 Q4	$14K	Sell	325 -8,638	-96%	-$388K	﹤0.01%	6906
2017 Q3	$493K	Buy	+8,963	New	+$1.51M	﹤0.01%	4138

Other funds holding SIOX

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citigroup's SIOX Position: Q1 2020 in Review

Citigroup sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2020, closing a stake of 5 shares — an estimated $18 sold.

Citigroup first reported a position in SIOX in Q4 2015 and held it in 17 quarters. The position peaked at $5.16M in Q2 2017. 42 funds tracked by Wall St. Rank hold SIOX as of Q1 2020.

Citigroup reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Citigroup sold 5 Sio Gene Therapies Inc. Common Stock shares in Q1 2020, an estimated $18.
Citigroup first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2015 and held it in 17 quarters.
Citigroup's Sio Gene Therapies Inc. Common Stock position peaked at $5.16M in Q2 2017.
42 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2020.

Based on Citigroup's 13F filing for Q1 2020, filed 12 May 2020.